Opendata, web and dolomites

KIT

Kidney Injury Technology

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 KIT project word cloud

Explore the words cloud of the KIT project. It provides you a very rough idea of what is the project "KIT" about.

patented    35    validation    commercialization    thorough    deadly    2018    gt       critical    reference    started    128    worldwide    rate    poses    income    population    company    smes    laid    sought    yearly    ivd    aki    global    69    transfer    samples       health    license    companies    diagnostics    yield    penetration    inren    regulated    10    acquire       upfront    initially    incident    renal    billion    acute    sme    unitary    price    vitro    channels    consolidation    gold    elevated    economic    clinical    prototype    capacity    royalties    650    patient    grows    2017    marker    instrument    2023    elisa    sales    clinically    international    handling    prognosis    technological    expenditure    diagnostic    incidence    biomarker    reduce    transferability    disease    kit    revolutionary    market    human    competitors    envisioned    bio    huge    people    standard    thereafter    dismally    sale    manufacturing    posing    maturity    tests    annual      

Project "KIT" data sheet

The following table provides information about the project.

Coordinator
BIO-INREN SL 

Organization address
address: NORBERTO CUESTA DUTARI 39 4 D
city: SALAMANCA
postcode: 37007
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.bio-inren.es
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-11-01   to  2015-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIO-INREN SL ES (SALAMANCA) coordinator 50˙000.00

Map

 Project objective

Bio-inRen has developed and patented a revolutionary biomarker-based diagnostic system for a highly and increasingly incident (>10% yearly) and dismally deadly disease (Acute Renal Failure -AKI) posing a huge global health and economic problem worldwide. Bio-inRen’s diagnostic system is envisioned to 1) change the concept and approach to AKI clinical handling, 2) become a reference diagnostic, 3) reduce AKI incidence (by 2.5-5% initially) and improve patient prognosis, and 4) reduce the elevated cost associated to AKI (1% of their global health expenditure, which will be reduced initially in 650 M € in this 1.35 billion people population). An ELISA-based, clinically useful prototype kit has been developed for measurement of human samples. Clinical validation has started, although Bio-inRen’s system needs thorough clinical validation to acquire technological maturity and transferability, for which Phase I and II SME instrument are necessary, on which all the company’s resources will be laid. As a new concept, Bio-inRen’s technology has no competitors in the market or under development. The In Vitro Diagnostic Market grows at a 7% annual rate and will reach $69.1 billion by 2017. AKI-specific market is estimated at 3.5 M cases and 70 M diagnostic tests of the existing gold standard marker. Because Diagnostics is a global and regulated market, Bio-inRen will license the system to large companies and SMEs in the IVD market with manufacturing capacity and international commercialization channels. Technology transfer is expected by 2018 to yield 1 M € upfront and 5% royalties on sales thereafter. 5% market penetration is sought by 2023. As of today, 5% of 70 M tests poses 3.5 M tests as Bio-inRen’s market (6.4 M tests by 2023 at 7% annual growth rate). At a unitary sale price of 20 €/test, this means 128 M €. 5% royalties will produce a yearly income of 6.4 M € to Bio-inRen, which are critical for the consolidation and growth of the company.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More